Intra-Cellular reports 3Q loss

NEW YORK (AP) _ Intra-Cellular Therapies Inc. (ITCI) on Wednesday reported a loss of $22.9 million in its third quarter.

On a per-share basis, the New York-based company said it had a loss of 53 cents.

The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 58 cents per share.

The biopharmaceutical company posted revenue of $30,754 in the period. Its adjusted revenue was $31,000.

Intra-Cellular shares have decreased 3 percent since the beginning of the year. The stock has climbed 21 percent in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ITCI at https://www.zacks.com/ap/ITCI